A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.

Journal: Nature communications
Published Date:

Abstract

In cancer, the primary tumour's organ of origin and histopathology are the strongest determinants of its clinical behaviour, but in 3% of cases a patient presents with a metastatic tumour and no obvious primary. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we train a deep learning classifier to predict cancer type based on patterns of somatic passenger mutations detected in whole genome sequencing (WGS) of 2606 tumours representing 24 common cancer types produced by the PCAWG Consortium. Our classifier achieves an accuracy of 91% on held-out tumor samples and 88% and 83% respectively on independent primary and metastatic samples, roughly double the accuracy of trained pathologists when presented with a metastatic tumour without knowledge of the primary. Surprisingly, adding information on driver mutations reduced accuracy. Our results have clinical applicability, underscore how patterns of somatic passenger mutations encode the state of the cell of origin, and can inform future strategies to detect the source of circulating tumour DNA.

Authors

  • Wei Jiao
    Department of Spinal Surgery, Fuyang City People's Hospital, Fuyang Anhui, 236000, P.R.China.
  • Gurnit Atwal
    Computational Biology Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Paz Polak
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Rosa Karlic
    Bioinformatics Group, Division of Molecular Biology, Department of Biology, Faculty of Science, University of Zagreb, Horvatovac 102a, Zagreb, Croatia.
  • Edwin Cuppen
    Hartwig Medical Foundation, Science Park 408, Amsterdam, The Netherlands.
  • Alexandra Danyi
    Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Jeroen de Ridder
    Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Carla van Herpen
    Radboud University Medical Center, Nijmegen, The Netherlands.
  • Martijn P Lolkema
    Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Neeltje Steeghs
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Gad Getz
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Quaid D Morris
    Vector Institute, Toronto, ON, Canada.
  • Lincoln D Stein
    Adaptive Oncology Program, Ontario Institute for Cancer Research, Toronto M5G 0A3, Canada.